STOCK TITAN

Mannkind Corp - MNKD STOCK NEWS

Welcome to our dedicated news page for Mannkind (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mannkind's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mannkind's position in the market.

Rhea-AI Summary
MannKind Corporation (MNKD) Reports 56% Increase in Total Revenues to $51M in 3Q 2023; Net Income at $2M
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
-
Rhea-AI Summary
MannKind Corporation has successfully enrolled 141 patients in the Phase 4 clinical trial INHALE-3, which is evaluating inhaled insulin for adults with type 1 diabetes. The study will compare A1c levels after switching to inhaled insulin from injectable insulin or pumps. Initial meal data will be presented in 1Q 2024, followed by the primary endpoint analysis in 2Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.07%
Tags
-
Rhea-AI Summary
MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial results. The company's management will host a conference call to discuss these results and corporate updates on November 7, 2023, at 5:00 PM (Eastern Time). The conference call can be accessed through the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
Rhea-AI Summary
MannKind Corporation announces a new patent for MNKD-101, an inhaled clofazimine suspension, for the potential treatment of nontuberculous mycobacterial (NTM) lung disease. The patent will expire on June 8, 2039.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.39%
Tags
none
-
Rhea-AI Summary
MannKind Corporation to participate in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences
-
Rhea-AI Summary
MannKind Corporation reports 2Q 2023 total revenues of $49M, a 157% increase YoY. Tyvaso DPI royalties increase by 63% compared to 1Q 2023. Endocrine Business Unit net revenues of $18M, Afrezza net revenues increase by 27% YoY. Income from operations of $2M, Non-GAAP income from operations of $8M. Commercial product gross margin improves to 72%. Cash, cash equivalents, and investments as of June 30, 2023, were $146.6M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.48%
Tags
Rhea-AI Summary
MannKind CEO to participate in one-on-one meetings at Wedbush PacGrow Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
Rhea-AI Summary
MannKind Corporation will release its 2023 Q2 financial results and year to date financial results on August 7, 2023. The company's CEO and CFO will host a conference call to discuss these results and corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
Rhea-AI Summary
MannKind Corporation announces a manufacturing milestone and hosts Connecticut Governor for a tour of its headquarters. The company has successfully scaled-up operations for increased production capacity of Tyvaso DPI® through its partnership with United Therapeutics. Construction is ongoing for new manufacturing space to expand production. MannKind has experienced over a 250% increase in its Connecticut workforce in the past two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Mannkind Corp

Nasdaq:MNKD

MNKD Rankings

MNKD Stock Data

1.12B
265.99M
1.53%
50.18%
11.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Westlake Village

About MNKD

mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.